SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 30, Issue 1, 2012, Pages 110-112

More than just an oncogene translocation and a kinase inhibitor: Kevin's story

(1) Costa, Daniel B a

a HARVARD MEDICAL SCHOOL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MICROTUBULE ASSOCIATED PROTEIN 4;

ADVANCED CANCER; BACKACHE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER STAGING; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; DYSPNEA; ECHINODERM; ENZYME ACTIVITY; EXERCISE; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE FUSION; GENE MUTATION; GENE TRANSLOCATION; HEADACHE; HISTOPATHOLOGY; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG EMBOLISM; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MICROSCOPE; MUSIC; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PLEURA; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; SHORT SURVEY; THORAX PAIN; TUMOR;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; ENZYME ACTIVATION; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; NARRATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84855561777 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2011.39.4486 Document Type: Short Survey

Times cited : (7)

References (10)

1
- 77954827460
- The path to personalized medicine
- Hamburg MA, Collins FS: The path to personalized medicine. N Engl J Med 363:301-304, 2010
- (2010) N Engl J Med , vol.363 , pp. 301-304
- Hamburg, M.A.¹ Collins, F.S.²

2
- 2342624080
- EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy
- DOI 10.1126/science.1099314
- Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
- (2004) Science , vol.304 , Issue.5676 , pp. 1497-1500
- Paez, J.G.¹ Janne, P.A.² Lee, J.C.³ Tracy, S.⁴ Greulich, H.⁵ Gabriel, S.⁶ Herman, P.⁷ Kaye, F.J.⁸ Lindeman, N.⁹ Boggon, T.J.¹⁰ Naoki, K.¹¹ Sasaki, H.¹² Fujii, Y.¹³ Eck, M.J.¹⁴ Sellers, W.R.¹⁵ Johnson, B.E.¹⁶ Meyerson, M.¹⁷

3
- 2342471392
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
- DOI 10.1056/NEJMoa040938
- Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
- (2004) New England Journal of Medicine , vol.350 , Issue.21 , pp. 2129-2139
- Lynch, T.J.¹ Bell, D.W.² Sordella, R.³ Gurubhagavatula, S.⁴ Okimoto, R.A.⁵ Brannigan, B.W.⁶ Harris, P.L.⁷ Haserlat, S.M.⁸ Supko, J.G.⁹ Haluska, F.G.¹⁰ Louis, D.N.¹¹ Christiani, D.C.¹² Settleman, J.¹³ Haber, D.A.¹⁴

4
- 4444344330
- EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
- DOI 10.1073/pnas.0405220101
- Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 (Pubitemid 39209661)
- (2004) Proceedings of the National Academy of Sciences of the United States of America , vol.101 , Issue.36 , pp. 13306-13311
- Pao, W.¹ Miller, V.² Zakowski, M.³ Doherty, J.⁴ Politi, K.⁵ Sarkaria, I.⁶ Singh, B.⁷ Heelan, R.⁸ Rusch, V.⁹ Fulton, L.¹⁰ Mardis, E.¹¹ Kupfer, D.¹² Wilson, R.¹³ Kris, M.¹⁴ Varmus, H.¹⁵

5
- 34547638047
- Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
- DOI 10.1038/nature05945, PII NATURE05945
- Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007 (Pubitemid 47206930)
- (2007) Nature , vol.448 , Issue.7153 , pp. 561-566
- Soda, M.¹ Choi, Y.L.² Enomoto, M.³ Takada, S.⁴ Yamashita, Y.⁵ Ishikawa, S.⁶ Fujiwara, S.-I.⁷ Watanabe, H.⁸ Kurashina, K.⁹ Hatanaka, H.¹⁰ Bando, M.¹¹ Ohno, S.¹² Ishikawa, Y.¹³ Aburatani, H.¹⁴ Niki, T.¹⁵ Sohara, Y.¹⁶ Sugiyama, Y.¹⁷ Mano, H.¹⁸

6
- 79952232216
- Global cancer statistics
- Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
- (2011) CA Cancer J Clin , vol.61 , pp. 69-90
- Jemal, A.¹ Bray, F.² Center, M.M.³

7
- 78049425319
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
- Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
- (2010) N Engl J Med , vol.363 , pp. 1693-1703
- Kwak, E.L.¹ Bang, Y.J.² Camidge, D.R.³

8
- 70349863393
- Cancer research: Looking for a target on every tumor
- Kaiser J: Cancer research: Looking for a target on every tumor. Science 326:218-220, 2009
- (2009) Science , vol.326 , pp. 218-220
- Kaiser, J.¹

9
- 70349464846
- Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway
- Nguyen KS, Kobayashi S, Costa DB: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10:281-289, 2009
- (2009) Clin Lung Cancer , vol.10 , pp. 281-289
- Nguyen, K.S.¹ Kobayashi, S.² Costa, D.B.³

10
- 79957487193
- CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib
- Costa DB, Kobayashi S, Pandya SS, et al: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29:e443-e445, 2011
- (2011) J Clin Oncol , vol.29
- Costa, D.B.¹ Kobayashi, S.² Pandya, S.S.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.